Actionable news
0
All posts from Actionable news
Actionable news in BMY: BRISTOL-MYERS SQUIBB CO.,

Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that 17 abstracts have been accepted for presentation at The Liver Meeting® 2015, the annual meeting of The American Association for the Study of Liver Diseases (AASLD) 2015, taking place in San Francisco, CA., from November 13 – 17.

“We are aiming to ultimately help a diverse range of hepatitis C patient populations.”

Tweet this

Highlights include:

  • Real-world data in chronic hepatitis C (HCV) populations, including genotype 3 patients, post-liver transplant patients, patients with advanced liver disease (including decompensated cirrhosis) and those coinfected with HIV.
  • Late-breaking data from the ALLY-3+ clinical trial, a study of Daklinza (daclatasvir) and sofosbuvir with ribavirin in genotype 3 HCV patients with cirrhosis.

“The data to be presented at this year’s AASLD conference reinforces Bristol-Myers Squibb’s ongoing commitment to investigating Daklinza-based treatments that could address the still-challenging needs of many patients living with chronic viral hepatitis C,” said Douglas Manion, M.D., head of Specialty Development, Bristol-Myers Squibb. “We are aiming to ultimately help a diverse range of hepatitis C patient populations.”

The complete list of Bristol-Myers Squibb data presentations follows. More information is available at http://www.aasld.org/.

...
Title Date/Time

Oral Presentation: All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study

Session: Late-breaking Abstract Session

Date: November 16, 2015

Session Time: 3:00 – 4:30 p.m.

Publication Number: LB-3

Oral Presentation: Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program

Session: Parallel 5:Hepatitis C:Pre-Approval Clinical Studies I

Date: November 15, 2015

Session Time: 3:00 - 4:30 p.m.

Presentation Time: 3:00 - 3:15 p.m.

Location: General Session/3000 (Moscone Center)

Publication Number: 37

Oral Presentation: Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program

Session: Viral Hepatitis Plenary

Date: November 17, 2015

Session Time: 8:00 - 9:30 a.m.

Presentation Time: 8:15 - 8:30 a.m.

Location: Room 3000 (Moscone Center)

Publication Number: 206

Oral Presentation: Daclatasvir and Sofosbuvir in Patients with Recurrent HCV Following Liver Transplantation and Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol

Session: Parallel 32: Clinical Aspects of HCV Virology, Pathogenesis, and Immunology

Date: November 17, 2015

Session Time: 11:15 a.m. -12:45 p.m.

Presentation Time: 12:00 -12:15 p.m.*

Location: Room 3014 (Moscone Center)

Publication Number: 217

* Presentation time expected to change, TBC

Oral Presentation: Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program

Session: Parallel 37: Hepatitis C: Pre-Approval Clinical Studies II

Date: November 17, 2015

Session Time: 11:15 a.m. - 12:45 p.m.

Presentation Time: 12:30 - 12:45 p.m.

Location: General Session/3000 (Moscone Center)

Publication Number: 252

Presidential Poster of Distinction: 702 Short-duration therapy with daclatasvir/asunaprevir/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward Study)

Session: Therapeutics: New Agents (not approved, Phase 2-3)

Date: November 14, 2015

Presentation Time: 2:00 – 7:30 p.m.

Location: Poster Hall

Publication Number: 702

Presidential Poster of Distinction: Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter compassionate use program


More